The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

The development of BCR:: ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …

Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is a neoplastic
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …

Chronic myeloid leukemia (CML) has been a model disease in the development of targeted
therapies. After nearly 40 years of the recognition of the chromosomal abnormality that …

In 2020, for the great majority of patients with chronic phase chronic myeloid leukemia
(CML), life expectancy is unaffected by a diagnosis of CML because of the unparalleled …

The chronic myeloid leukemia (CML) therapeutic landscape has dramatically changed with
tyrosine kinase inhibitor (TKI) development, which allows a near-normal life expectancy …

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

Summary Background Tyrosine kinase inhibitors (TKIs) have improved the survival of
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …

Opinion statement Strict criteria for when to stop tyrosine kinase inhibitor (TKI) therapy in
clinical practice are not easily defined without an agreement on what probability of achieving …

The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …